Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Patients with GH-secretory pituitary adenomas who did or did not achieve a normalized IGF-1 level before their most recent MR imaging
Characteristic Normalized IGF-1 (95% CI) (n = 9) Elevated IGF-1 (95% CI) (n = 7) Difference (95% CI) P Value
Extraocular muscle size at most recent MR imaging (mm) 3.9 (3.6–4.2) 4.7 (4.3–5.0) 0.7 (0.3–1.2) <.001
Average IGF-1/ULN at diagnosis 1.9 (1.5–2.3) 2.8 (2.3–3.4) 0.9 (0.2–1.5) .010
Size of pituitary adenoma (mm) 19.1 (15.9–22.3) 23.9 (17.4–30.3) 4.7 (−2.1–11.6) .170
Average duration of elevated IGF-1 (mo) 20.4 (12.4–28.5) 39.3 (18.8–59.9) 18.9 (−2.3–40.1) .078
Average time between initial and final MR imaging (mo) 52.8 (26.1–79.4) 39.9 (19.7–60.1) −12.9 (−45.0–19.1) .417

Characteristic	Normalized IGF-1 (95% CI) (n = 9)	Elevated IGF-1 (95% CI) (n = 7)	Difference (95% CI)	P Value
Extraocular muscle size at most recent MR imaging (mm)	3.9 (3.6–4.2)	4.7 (4.3–5.0)	0.7 (0.3–1.2)	<.001
Average IGF-1/ULN at diagnosis	1.9 (1.5–2.3)	2.8 (2.3–3.4)	0.9 (0.2–1.5)	.010
Size of pituitary adenoma (mm)	19.1 (15.9–22.3)	23.9 (17.4–30.3)	4.7 (−2.1–11.6)	.170
Average duration of elevated IGF-1 (mo)	20.4 (12.4–28.5)	39.3 (18.8–59.9)	18.9 (−2.3–40.1)	.078
Average time between initial and final MR imaging (mo)	52.8 (26.1–79.4)	39.9 (19.7–60.1)	−12.9 (−45.0–19.1)	.417